CRISPR/Cas9-mediated disruption of the insulin-like growth factor 2 (IGF2) gene in KYSE-150 cells generates a polyclonal knockout cell population suitable for studying IGF2-dependent oncogenic processes. This polyclonal pool, derived from the human esophageal squamous cell carcinoma line KYSE-150, contains a heterogeneous mixture of gene-edited alleles that collectively abolish functional IGF2 expression. The use of a polyclonal population avoids clonal selection artifacts and allows assessment of pooled loss-of-function effects.
The KYSE-150 cell line is a well-characterized model of esophageal squamous cell carcinoma, exhibiting adherent epithelial morphology and carrying a TP53 mutation that inactivates p53 tumor suppressor function. This line is widely employed for research on esophageal carcinogenesis, including studies of proliferation, invasion, and therapeutic resistance. The TP53-deficient background enhances tumorigenic potential and provides a relevant context for examining cooperating oncogenic pathways.
IGF2 is a fetal growth factor and mitogen that activates the IGF1 receptor (IGF1R) and insulin receptor (INSR), initiating signal transduction cascades. Ligand binding recruits IRS1, which activates PIK3CA and subsequently AKT1. AKT1 phosphorylates downstream effectors such as mTOR, GSK3B, and FOXO1, driving cell proliferation and survival. Simultaneously, IGF2 stimulates the MAPK pathway via MAPK1/3 (ERK1/2), further promoting mitogenic responses. IGF2 expression is regulated by imprinting at the H19/IGF2 locus and by transcription factors PLAG1, SP1, and EGR1. Bioavailability is modulated by IGF-binding proteins (IGFBP1-7) and the clearance receptor IGF2R. Crosstalk with integrin signaling influences focal adhesion dynamics.
In KYSE-150 cells, IGF2 overexpression contributes to autocrine/paracrine growth stimulation and malignancy. CRISPR/Cas9-mediated IGF2 disruption in this TP53-mutant background is expected to impair PI3K/AKT and MAPK/ERK signaling, reducing proliferation, increasing apoptosis, and attenuating migratory capacity. This polyclonal knockout model enables functional investigation of IGF2 dependency in esophageal cancer without the bias of single-clone expansion, making it suited for studying pathway addiction and resistance mechanisms.
This product supports a range of applications, including analysis of IGF2-driven proliferation and apoptosis by MTT and Annexin V assays, evaluation of downstream phospho-AKT and phospho-ERK by immunoblotting, and assessment of cell migration and invasion via Transwell assays. Cell cycle distribution can be examined by flow cytometry, and global transcriptomic changes by RNA-seq. In vivo tumorigenicity studies using xenograft models further extend the utility of these cells. For additional information or to discuss customized knockout projects, contact Ascent Research.
